New hope for advanced prostate cancer: drug cocktail trial launches
NCT ID NCT07198633
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 27 times
Summary
This study tests two experimental drugs, QLC5508 and QLH12016, alone or with standard hormone therapies (abiraterone or enzalutamide) in 212 men with advanced prostate cancer that has spread. The goal is to find safe doses and see if the combinations shrink tumors or lower PSA levels. Participants must have metastatic disease and be in relatively good health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.